TomoTherapy to Acquire Linear Accelerator Manufacturer in China

MADISON, Wis.--(Business Wire)--
TomoTherapy Incorporated (NASDAQ: TOMO), maker of the Hi-Art(R)
treatment system for advanced radiation therapy, announced today that
it has entered into an agreement to acquire privately held linear
accelerator manufacturer Chengdu Twin Peak Accelerator Technology
Inc., based in Chengdu, China.

A linear accelerator (linac) is a key component in radiation
therapy systems, used to create high-energy x-rays for cancer
treatments. The linear accelerators designed, developed and
manufactured by Twin Peak will be used to supplement TomoTherapy's
existing supply source.

According to Fred Robertson, CEO of TomoTherapy: "We are very
pleased to make this announcement. The acquisition of Twin Peak
represents a substantial advance in our ability to control the quality
and features of our products. This is also a piece of our longer-term
strategy of reducing the cost of the Hi-Art treatment system to
improve margins."

The financial terms of the transaction were not disclosed.
TomoTherapy anticipates that the transaction will close in
approximately 90 days.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the
TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation
therapy system for the treatment of a wide variety of cancers. The
Hi-Art treatment system combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with
speed and precision while reducing radiation exposure to surrounding
healthy tissue. The company's stock is traded on the NASDAQ Global
Select Market under the symbol TOMO. To learn more about TomoTherapy,
please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future business, plans,
events, expectations, products and other similar matters, including
but not limited to statements using the terms "anticipates", "will"
and "may", constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements contained in this press release are subject
to risks and uncertainties that could cause actual results to differ
materially from those anticipated, including but not limited to
factors such as our ability to integrate acquired assets, reliance on
a sole or limited source, ability to increase gross margins, ability
to protect intellectual property, risks of interruption due to events
beyond the company's control, and the other risks listed from time to
time in TomoTherapy's filings with the U.S. Securities and Exchange
Commission, which by this reference are incorporated herein. These
forward-looking statements represent TomoTherapy's judgments as of the
date of this press release. TomoTherapy assumes no obligation to
update or revise the forward-looking statements in this release
because of new information, future events or otherwise.

(C)2008 TomoTherapy Incorporated. All rights
reserved. TomoTherapy, the TomoTherapy logo and Hi-Art are among
trademarks, service marks or registered trademarks of TomoTherapy
Incorporated.

TomoTherapy Incorporated
Investor Contact:
Stephen C. Hathaway
Chief Financial Officer
608.824.2800
shathaway@tomotherapy.com
or
Media Contact:
Patty Kitowski
Marketing Communications Manager
608.824.2820
pkitowski@tomotherapy.com

Copyright Business Wire 2008